Latest Ground Zero Pharmaceuticals Inc. Stories

IRVINE, Calif., Nov. 14, 2012 /PRNewswire/ -- GZP is announcing expansion of its longstanding capabilities in helping its clients develop biosimilars and drug or biologic/diagnostic device personalized medicine programs for FDA and EMA review. New legislative initiatives in the US and subsequent regulations and guidelines have provided a number of pathways for development of biosimilars, with the associated requirements for intensive planning and execution of nonclinical and clinical...

IRVINE, Calif., Oct. 27, 2011 /PRNewswire/ -- GZP is announcing expansion of its client oncology programs, from strategic and regulatory consulting through product development and clinical trial execution, of pharmaceutical and biological therapies. These include treatment vaccines, somatic cell and gene therapies, and novel small molecules. Senior associates with oncology expertise in nonclinical, manufacturing, and clinical development provide clients with hands-on guidance throughout...

IRVINE, Calif., Oct. 5 /PRNewswire/ -- GZP is pleased to announce that it has expanded its capabilities for strategic regulatory and product development support of gene therapy and somatic cell therapies, including treatment vaccines for cancer and other serious or life-threatening diseases. New senior associates with expertise in manufacturing and clinical development in these expanding areas allow GZP to provide its clients with hands-on guidance through the FDA regulatory review...

IRVINE, Calif., Oct. 6 /PRNewswire/ -- A major increase in innovative concepts for exciting therapeutic and preventive new products in Australia has led to an expansion of GZP's activities Down Under, to better support clients in their efforts to take their programs to the US Food and Drug Administration. Our new office in downtown Brisbane, Australia was established on July 1 and we are adding Australia-based associates with FDA, TGA and EMEA experience to expand access to our worldwide...